Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

By November 15, 2018

The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

By November 12, 2018

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child-Pugh class A liver impairment.

Nirogacestat Gets Fast-Tracked for the Treatment of Desmoid Tumors

By November 08, 2018

The Company is planning a Phase 3 study (DeFi) sometime in the first half of 2019.

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma

November 08, 2018

The researchers found that median progression-free survival was 10.3 and 4.7 months in the elotuzumab and control groups, respectively, after a minimum follow-up period of 9.1 months.

FDA Approves Additional Multiple Myeloma Indication for Empliciti

By November 07, 2018

Approval was based on results from ELOQUENT-3, a Phase 2, open-label trial (N=117) involving patients with relapsed or refractory multiple myeloma.

Organic food consumption linked to reduced cancer risk

November 07, 2018

This study is a prospective cohort that evaluated self-reported organic food consumption and incidence of cancer, while adjusting for known cancer risk factors.

Dermatologic Adverse Events Common With Targeted Therapies, Immunotherapies

By November 06, 2018

"Closer collaboration between dermatologists and oncologists is essential," write the authors.

Lorbrena Approved for Previously-Treated ALK-Positive Metastatic NSCLC

By November 05, 2018

Lorbrena, a third generation ALK tyrosine kinase inhibitor (TKI), has been approved under the accelerated pathway based on tumor response rate and duration of response.

Age to Stop Cervical Cancer Screening Depends on Test Used

November 05, 2018

The model predicted lifetime risk for cervical cancer to be 1 in 45 for women without HPV vaccination who have never been screened. Incremental decreases in cancer risk were seen later in life with increasing age at which women stopped cytology screening from 55 to 75 years.

Keytruda Combo Approved for First-Line Tx of Metastatic Squamous NSCLC

By October 31, 2018

The approval was supported by data from the Phase 3 randomized, double-blind, multicenter, placebo-controlled KEYNOTE-407 trial.

Mitomycin Gel Granted Breakthrough Tx Designation for Urothelial Cancer

By October 31, 2018

UGN-1 is an investigational formulation of mitomycin, delivered to patients using standard intravesical catheters.

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

By October 29, 2018

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.

Durvalumab Extends Survival vs Placebo in Stage 3 Non-Small Cell Lung CA

October 29, 2018

Overall survival was significantly prolonged with durvalumab versus placebo (stratified hazard ratio [HR] for death, 0.68; P=.0025). For progression-free survival, the median duration was 17.2 months in the durvalumab group and 5.6 months in the placebo group.

Healthier Diet Tied to Lower Mortality Risk in CRC Patients

October 29, 2018

Among participants with a low diet quality before diagnosis, improvement in DASH (HR, 0.54) and prudent scores (HR, 0.53) was associated with lower CRC-specific mortality.

Long-Term Benefit for Stereotactic Radn in Prostate CA

October 29, 2018

Overall, 95.5, 91.4, and 85.1% of patients were free from BCR at 7 years in the low-risk, favorable intermediate-risk, and unfavorable intermediate-risk groups, respectively. The corresponding overall survival rates were 91.4, 93.7, and 86.5%, respectively.

Generic Version of Trisenox Now Available

By October 26, 2018

Arsenic Trioxide, an arsenical, is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

New Formulation of Levoleucovorin Gets FDA Approval

By October 23, 2018

Khapzory will be supplied in single-dose vials containing 175mg and 300mg of levoleucovorin lyophilized powder for reconstitution before intravenous administration.

Organic Food Consumption and Cancer Risk: What's the Link?

By October 22, 2018

To investigate the link between organic food consumption and cancer risk, study authors conducted a population-based prospective cohort study among French adults.

Palonosetron Available in Prefilled Syringe for Chemotherapy-Induced Nausea, Vomiting

By October 22, 2018

The prefilled syringe is part of the Company's Simplist portfolio and is the first FDA-approved prefilled delivery version of palonosetron hydrochloride (HCI) to become available.

Paternal Methotrexate Use and Congenital Malformations: Is There Any Link?

October 22, 2018

Data was pulled from the PubMed, Embase, Cochrane Central, and CINAHL databases to study possible links between men using methotrexate and congenital malformations in offspring.

Treatment Tied to Survival Benefit in Complex Bladder Cancer

October 17, 2018

The researchers found that treatment was associated with a 30% reduction in death, while having multiple complex conditions was associated with a 72% increase in death in unweighted multivariable analysis.

Lynparza Granted Orphan Drug Status for Pancreatic Cancer

By October 17, 2018

Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor, is being assessed in the ongoing Phase 3 POLO trial.

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

By October 16, 2018

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Survival Time Compared for Brigatinib vs Crizotinib in NSCLC

October 16, 2018

The researchers found that the rate of progression-free survival was higher with brigatinib compared with crizotinib (estimated 12-month progression-free survival, 67% vs 43%; hazard ratio for disease progression or death, 0.49).

STRO-001 Gets Orphan Drug Designation for Mutiple Myeloma

By October 12, 2018

STRO-001 targets CD74, which is a protein highly expressed in B-cell malignancies like multiple myeloma.

Low-Dose Aspirin May Reduce Ovarian Cancer Risk

October 12, 2018

When current use vs. non-use of any aspirin was evaluated, significant associations between aspirin and cancer risk were not observed, regardless of aspirin dose.

Long-Term Aspirin Use May Reduce Liver Cancer Risk

October 10, 2018

"Further research appears to be needed to clarify whether aspirin use represents a feasible strategy for primary prevention against HCC," the authors write.

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL

October 10, 2018

The researchers found that all patients met the primary end point, with significant improvement in progression-free survival per Independent Review Committee assessment compared with ofatumumab (median, 13.3 vs. 9.9 months; hazard ratio, 0.52), including those with high-risk chromosome 17p13.1 deletions (del[17p]) and/or TP53 mutations (hazard ratio, 0.4).

Gardasil 9 Approved for Use in Women and Men 27 Through 45 Years Old

By October 09, 2018

The approval of the expanded age range was based on data from a clinical trial which evaluated the efficacy of Gardasil (quadrivalent human papillomavirus recombinant vaccine) in 3253 women 27-45 years of age with a median duration of follow-up of 3.5 years post-dose 3.

FDA Amends Food Additive Regulations to No Longer Allow Use of 7 Substances

By October 05, 2018

The petition was submitted by a number of non-profit organizations including the Center for Science in the Public Interest and the Breast Cancer Fund.